Comparison of verapamil and bepridil in the therapy of familiar cardiomyopathy of the Syrian hamster

  • B. Kunkel
  • U. Hofmann
  • M. Mutschler
Conference paper

Abstract

The effect of verapamil on the cardiomyopathic hamster is wellknown from the basic works of Loßnitzer (6–9). It is not known, however, whether different calcium-antagonists have the same cardioprotective potency. In this study we analyzed the effect of bepridil, on the cardiomyopathic hamster. Bepridil is shown to be a calcium antagonistic drug (10) with documented antianginal (1) in humans efficacy.

Keywords

Formalin Magnesium Ischemia Luminal Cardiomyopathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Canicave JC, Den J, Jacq Z, Paillet R (1980) Therapie 35: 607PubMedGoogle Scholar
  2. 2.
    Factor S, Minase T, Cho S, Dominitz R, Sonnenblick E (1985) Microvascular spasm in the cardiomyopathic Syrian hamster: A preventable cause of focal myocardial necrosis. Circulation 66: 342–354CrossRefGoogle Scholar
  3. 3.
    Fleckenstein A, Janke J, Döring HJ, Leder O (1971) Die intracelluläre Überladung mit Calcium als entscheidender Kausalfaktor bei der Entstehung nicht coronarogener Myokardnekrosen. Verh Dtsch Ges Kreislaufforsch 37: 345–353PubMedCrossRefGoogle Scholar
  4. 4.
    Fleckenstein A, Janke J, Döring HJ, Pachinger O (1973) Ca overload the determinant factor in the production of catecholamine-induced myocardial lesion. In: Bajusz E, Rona G (eds) Cardiomyopathies. Recent in the Study of Cardiac Structural Metabolism. Advances Vol 2. University Park Press, Baltimore—London—Tokyo, pp 455–466Google Scholar
  5. 5.
    Fleckenstein A, Frey M, Keidel JJ (1982) Prevention by Verapamil of Isoproterenol-induced hypertrophie cardiomyopathy in rats. In: M Kaltenbach, S Epstein (eds) Hypertrophie cardiomyopathy. Springer Verlag, Berlin—Heidelberg-New York, pp 113–120Google Scholar
  6. 6.
    Loßnitzer K, Steinhard B, Grewe N, Stauch M (1975) Charakteristische Elektrolytveränderungen bei der erblichen Kardiomyopathie des Syrischen Goldhamsters (Stamm Bio 8262). Basic Res Cardiol 70: 508–520PubMedCrossRefGoogle Scholar
  7. 7.
    Loßnitzer K, Konrad A, Zeger D, Mohr W (1982) Prevention of myocardial cell necrosis in the Syrian hamster. Results of long-term treatment. In: M Kaltenbach, S Epstein (eds) Hypertrophie Cardiomyopathy. Springer Verlag, Berlin—Heidelberg—New York, pp 99–114CrossRefGoogle Scholar
  8. 8.
    Loßnitzer K (1975) Genetic Induction of a Cardiomyopathy. In: Born GVR, Eichler O, Farah A, Herken H, Welch AD (eds) Handbuch der experimentellen Pharmakologie. Vol XVI/3, Springer Verlag, Berlin—Heidelberg—New York, pp 309–344Google Scholar
  9. 9.
    Mohr W, LoBnitzer K (1974) Morphologische Untersuchungen an Hamstern des Stammes Bio 8262 mit erblicher Myopathie und Kardiomyopathie. Beitr Path 153: 178–193Google Scholar
  10. 10.
    Murphy KMM; Gould RJ, Largent BJ, Snyder SH (1983) Proc Natl Acad Sci USA 80: 860PubMedCrossRefGoogle Scholar
  11. 11.
    Weibel E, Kistler GS, Scherle WF (1966) Practical stereological methods for morphometric cytology. J Cell Biol 30: 23–38PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1988

Authors and Affiliations

  • B. Kunkel
    • 1
    • 2
    • 3
  • U. Hofmann
    • 1
    • 2
  • M. Mutschler
    • 1
    • 2
  1. 1.Medizinische PoliklinikUniversität ErlangenGermany
  2. 2.Institut für PharmakologieUniversität FrankfurtGermany
  3. 3.Medizinische PoliklinikUniversität ErlangenErlangenGermany

Personalised recommendations